Background: Disseminated tumor cells (DTCs) are detectable in the bone marrow (BM) of patients with primary breast cancer (PBC) and predictive of an impaired prognosis. This large trial aimed to analyze the impact of DTC detection on locoregional relapse (LR).
introduction
Breast cancer is a systemic disease that might relapse even in patients without lymph node involvement and despite complete resection of the primary tumor. Therefore, recurrent disease must arise from residual micrometastatic tumor cell populations that (i) abandon the primary tumor already during very early stages of disease, (ii) are not detected by standard imaging procedures and (iii) can rest in a 'dormant' state for years before they outgrow into macrometastases [1] .
An attractive surrogate for minimal residual disease are disseminated tumor cells (DTCs) that can be detected in the bone marrow (BM) of 20%-40% of the patients with primary breast cancer (PBC) [2] [3] [4] [5] [6] [7] [8] . A large pooled analysis, conducted in 2005 by Braun et al., demonstrated that the presence of cytokeratin positive DTCs at primary diagnosis is predictive of poor outcome [6] . Since then, these results have been confirmed in various independent studies [8] [9] [10] [11] . As DTC persistence during follow-up also is an indicator of impaired prognosis, the BM seems to serve as a homing site for dormant DTCs that can be precursors of a later metastatic relapse [12, 13] . Additionally, animal experiments suggest that tumor cells have the ability to (re)circulate into the blood stream and return to the primary tumor [14] . This process, called 'tumor self-seeding', might select for highly aggressive tumor cell clones and may contribute to the development locoregional relapse (LR). However, this hypothesis needs support from clinical studies [15] .
The purpose of this study was to evaluate the impact of DTC detection on locoregional recurrent disease in a large cohort of patients with PBC. Additionally, we reevaluated the clinical impact of the DTC status at the time of LR in a subgroup of patients.
methods study population
Women that underwent surgery for stage I-III primary invasive breast cancer (T1-4, N0-2, M0) at the Department of Gynecology and Obstetrics at Tuebingen University, Germany, between January 2001 and December 2013 were eligible for this analysis. Patient and tumor characteristics were recorded prospectively from medical files and pathology reports. In all patients, a baseline bone marrow aspiration (BMA1) was carried out during primary surgery. Exclusion criteria were metastatic disease, recurrent disease, bilateral breast cancer, preoperative (neoadjuvant) systemic treatment, R1/R2 resection or a previous history of secondary malignancy. All patients provided written informed consent for BM aspiration, and the analysis was approved by the ethics committee of Tuebingen University (reference number: 560/2012R).
systemic treatment
Systemic treatment of primary and locoregional recurrent disease was based on the current St Gallen recommendations and on national treatment guidelines (www.ago-online.de) and is presented in detail in supplementary Appendix, available at Annals of Oncology online.
follow-up and definition of locoregional relapse
Follow-up was carried out according to national guidelines (www.agoonline.de) and the data were recorded by the clinical cancer registry of the Comprehensive Cancer Center (CCC) of Tuebingen University, Germany. LR was defined as any invasive breast cancer that has relapsed for the first time in the ipsilateral breast, ipsilateral lymph nodes or ipsilateral chest wall. All LR had to be confirmed histologically. If surgery for LR was carried out at the Department of Gynecology and Obstetrics of Tuebingen University, Germany, patients were routinely offered a second BMA (BMA2). The following patients were excluded from the analysis of BMA2: (i) patients that received preoperative systemic treatment of LR, (ii) patients with inoperable LR, (iii) patients that had R1 or R2 resection of LR and (iv) patients that had metastasis-associated LR (i.e. LR after or less than 2 months before the occurrence of distant metastasis).
bone marrow status and immunhistochemistry
During surgery for primary (BMA1) or locoregional recurrent disease (BMA2), 10-20 ml of BM aspirates were collected from one anterior iliac crest. Samples were processed as in supplementary Appendix, available at Annals of Oncology online.
statistical analysis
Statistical analysis is presented in supplementary Appendix, available at Annals of Oncology online.
results

patient characteristics and DTC detection at BMA1
A total of 3072 PBC patients were eligible for the study. Patient characteristics are presented in detail in Table 1 . Most patients were postmenopausal (62%), had invasive ductal breast cancer (75%), were grade 1-2 (82%), had T1 tumors (68%) and were nodal negative (70%). The majority was ER/PR positive (82% and 70%, respectively) and HER2 was overexpressed in 12% of the patients. As shown in supplementary Appendix, available at Annals of Oncology online, most patients received breast-conserving surgery (69%) and radiotherapy (83%). Postoperative adjuvant systemic treatment consisted of endocrine treatment (82%) chemotherapy (48%), HER2-directed treatment (9%) and bisphosphonate treatment (28%). During primary surgery (BMA1), DTCs were detected in 731 of 3072 (24%) patients. As demonstrated in Table 1 , the presence of DTCs at BMA1 was associated with tumor size (P = 0.005) and the PR status (P = 0.012).
locoregional recurrent disease and DTC detection at BMA2
After a median follow-up of 44 [95% confidence interval (CI) 43-45] months, 139 patients experienced a LR, of whom 48 (35%) were initially DTC positive at BMA1 (supplementary Figure S1 , available at Annals of Oncology online). Locoregional recurrent disease was accompanied by synchronous or metachronous distant metastasis in 39 (28%) of the patients. Two patients (1%) were inoperable, three patients (2%) received preoperative systemic treatment and one patient (1%) had R1 resection. Thirty-nine patients did either not agree into BMA2 or underwent surgery for LR in another hospital. Hence, 55 patients were available for the analysis of the DTC status at BMA2. The median period of time between BMA1 and BMA2 was 42 months.
Tumor characteristics of LR and patient characteristics at BMA2 are shown in detail in Table 1 . Most patients were postmenopausal (87%) with grade 1-2 (59%) invasive ductal carcinoma (90%). The majority had a tumor size <2 cm (T1, 62%) were nodal negative (81%), ER-positive (59%), PR-negative (52%) and HER2 negative (85%). At BMA2, 17 of 55 (31%) patients presented with DTCs; 10 of these were initially DTC negative and 7 of these were DTC positive at BMA1 (supplementary Figure S1 , available at Annals of Oncology online). There was no significant association between the DTC status at BMA2 and any patient or tumor characteristics.
Treatment of LR is presented in detail in supplementary Appendix, available at Annals of Oncology online. Breast-conserving surgery for locoregional recurrent disease was carried out in 8 (14%) patients that refused total mastectomy when radiation therapy was available. Of note, one woman only received lymph node surgery as she had no intramammary relapse. Radiation therapy was carried out in 8 (16%) patients. Systemic treatment consisted of endocrine treatment (60%) chemotherapy (38%), HER2-directed treatment (10%) and bisphosphonate treatment (33%).
The DTC status at BMA1 was a significant predictor for locoregional recurrent disease in the univariate [hazard ratio (HR): 1.75; 95% CI 1.23-2.49; P = 0.005; Figure 1 ] and multivariate analysis (HR: 1.65; 95% CI 1.13-2.40; P = 0.009; Table 2 ). Next to the DTC status, other predictors for LR were nodal status, and the ER/PR status. Figure 2A and B, patients that were DTC positive at primary diagnosis had a significantly greater risk of distant metastatic relapse and death than did DTC-negative patients. The HR for distant metastatic relapse was 1.45 (95% CI 1.01-1.97; P = 0.017) and the HR for death was 1.57 (95% CI 1.93-2.08; P = 0.004). In the multivariate analysis (supplementary Table S1 , available at Annals of Oncology online), independent predictors of reduced DMFS were tumor grade, tumor size, nodal status, PR status and the DTC status. Independent predictors of reduced OS were menopausal status, tumor size, nodal status PR status and the DTC status. Median follow-up from BMA2 was 36 (95% CI 16-56) months for DMFS and 46 (95% CI 39-53) months for OS. Ten of 34 patients had developed distant metastatic disease and 15 of 48 patients had died. As demonstrated in Figure 2C and D, patients that were DTC positive at the time of LR had an increased risk of death than did DTC-negative patients (HR: 2.83; 95% CI 1.02-7.84; P = 0.037). There was, however, no significant impact of the DTC status at BMA2 on DMFS (P = 0.583).
discussion
Hematogenous tumor cell dissemination into the BM is associated with an increased risk of metastatic relapse and death. The aim of this study was to analyze the impact of DTC detection on LR. Next to clinical implications, this question has theoretical aspects on the biology of locoregional recurrence.
Discrepancies between detection rates of DTCs are mostly due to technical issues. Sampling, preparing and identification need to be standardized before DTC detection can be integrated into the clinical routine of breast cancer management. We recently confirmed the independent prognostic significance of DTCs in a large single-center analysis on more than 3000 women with PBC by using standardized guidelines for DTC detection that were recommended by an international expert consensus [8, 16, 17] . Interestingly, we found that neoadjuvant systemic therapy, original articles
Annals of Oncology applied before BM sampling increases the prevalence of DTC detection [8, 18] . This challenges the interpretation of the DTC status after systemic therapy and, therefore, we only included treatment naïve patients with PBC in our current analysis. Nevertheless, postoperative systemic therapy including the use of adjuvant bisphosphonate treatment improves outcome of DTCpositive patients [8, 19] . This biases the impact of DTC detection on event-free survival and might explain for the rather small survival differences we observed in DTC-positive versus DTC-negative patients. Earlier trials have evaluated the impact of DTC detection on locoregional recurrent disease. Bidard et al. analyzed the clinical impact of the DTC status in 612 patients with PBC [20] . The authors not only confirmed an impaired OS and DMFS in DTC-positive patients, but also found a significant impact of DTC detection on the risk of LR. Similar results were presented by Diel et al.; however, other trials found no significant association between the DTC status and LR [2, 5, 21] . These discrepant results are most likely due to technical issues and different patient collectives. Moreover, the number of patients that experienced LR was limited in these earlier studies and larger trials are needed to clarify the role of tumor cell dissemination into the BM for locoregional recurrent disease.
In the present analysis, LR was diagnosed in 139 patients. This rate of LR (4.5%) is similar to that presented by others [5, 7] . The current study, which is to our knowledge the largest study on the impact of DTC detection on LR, not only confirms the prognostic value of DTC detection on DMFS and OS but also demonstrates that DTC positivity is highly significant and independently associated with an increased risk of locoregional recurrent disease [2, 20] . The 'tumor-self-seeding' paradigm has been validated in mathematical, experimental and animal models and would explain for the association between DTC detection and LR [22] . It challenges the classical model of unidirectional cancer spread from the primary tumor to lymph nodes and metastatic sites and postulates that circulating tumor cells (CTCs) can travel to and from distant and primary tumor sites [14] . Against this background, the BM may act as a temporary site were DTCs can escape from local therapy, rest in a dormant state and finally recirculate within the body as a potential source of LR [23] . This would also explain for the high rate of synchronous distant metastasis we and others observed at the time of LR [20, 24] .
Another explanation for the association of LR and the DTC status would be that DTCs are a surrogate of higher tumor burden or more aggressive disease instead of being the source of locoregional recurrent disease. This is in line with our observation that the DTC status was associated with tumor size and tumor biology (PR status). Bidard et al. indicated that DTC-positive patients may benefit from larger irradiation fields [20] . However, a possible explanation in favor for the self-seeding hypothesis is that radiotherapy might prevent DTCs/CTCs from recolonization of the breast and lymph nodes [25] . In line with the results presented by Bidard et al., we found no association between nodal involvement and DTC detection [20] . Additionally, multivariate analysis revealed that DTC detection in the BM predicted LR independent of tumor size and tumor biology.
We reevaluated the DTC status in 55 patients at the time of LR. Although tumor size and nodal involvement in these patients was comparable with that of patients with PBC, the DTC detection rate seemed higher at the time of LR. Nevertheless, 24 patients that experienced an LR were neither DTC positive at BMA1 nor at BMA2. Other sites of tumor cell dormancy and/or lack of sensitivity of our method for DTC detection are possible explanations for this finding. Although survival analysis with regard to the DTC status at the time of LR was limited, which is due to the small number of patients, we found that the DTC detection at BMA2 was associated with poor OS. This observation is in line with earlier results on an impaired prognosis of patients that are DTC positive during follow-up [12, 13] . The DTC status might therefore indicate patients that are in need for more aggressive or additional systemic treatment. This hypothesis is strongly underlined by a recent prospective trial, demonstrating that DTC eradication with additional adjuvant docetaxel treatment is associated with improved survival [12] . Additionally, there is evidence that bisphosphonate treatment may eradicate DTCs from the BM [8, 19, 26, 27] .
One major limitation of DTC detection is the invasiveness of BM sampling, especially with respect to repeated analysis. Recent research has therefore focused on detection of CTCs from the peripheral blood. It remains, however, unclear whether the presence of DTCs is associated with CTC detection as results on that questions are inconclusive among the literature [10, [28] [29] [30] . Although CTC detection in patients with PBC was shown to correlate with early recurrence and decreased OS, low detection rates in nonmetastatic breast cancer make the use of this technology challenging [31, 32] . Moreover, there are, to our knowledge, no trials that specifically evaluate the impact of CTCs on locoregional recurrent disease.
In the future, breast cancer treatment will be more and more tailored to individual tumor characteristics. Given that systemic treatment is directed against minimal residual disease, the current practice of using primary tumor tissue to assess predictive markers may need to be queried [1] . Changes of the hormonal and HER2 receptor status from primary to metastatic tumor tissue are a known phenomenon, emphasizing the potential role of DTCs and CTCs for phenotypic characterization and molecular profiling [33, 34] . With respect to the concept of tumor self-seeding, phenotypic changes of DTCs and CTCs would also explain for switches in biomarker status between primary and locoregional recurrent breast cancer [35] . Currently, several prospective studies that address this important issue of DTCs and CTCs in primary as well as in metastatic breast cancer are ongoing (NCT01545648, NCT01779050, NCT01619111, NCT0154867).
In conclusion, we found that DTC detection is not only predictive of distant relapse and OS, but also indicates an increased risk for locally recurrent disease. The data we present derives from the largest single-center study on DTC determination in nonmetastatic breast cancer. As future applications for DTCs will include their phenotypic characterization, the standardized methodology we used not only supports the clinical validity of DTC detection, but also facilitates the adoption of BM sampling into clinical trials on personalized breast cancer management.
